Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:52:30.083Z.
Calculation as of: 2026-10-06T14:52:30.083Z.
Quote observation: 2026-10-06T14:50:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 219fbb4d6b0ca624999def179c3978493f715f11796d6849d3f6b20cded99b3d
PEG RATIO
N/A
Harmony Biosciences Holdings, Inc.
Market Cap
$2.26B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.26B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | $2.26B | N/A | N/A | N/A | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.26B | N/A | N/A | N/A | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.32B | N/A | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.35B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | N/A | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.36B | N/A | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.42B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 0.98 | 1.08 | 1.19 | 1.40 |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
12.7
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
